Application and Prospect of Gene Editing Technology in Immunotherapy
DOI:
https://doi.org/10.54097/814b9h72Keywords:
Gene editing technology, immunotherapy, tumor treatment, immune diseasesAbstract
Clinical medical practitioners are increasingly embracing CRISPR/Cas9 technology. While CRISPR/Cas9 technology provides powerful editing capabilities, it is also simple to operate, low in cost, and highly specific. Furthermore, this technology is capable of accurately and efficiently screening the entire genome in a short period of time, which is extremely valuable for gene diagnosis. This article focuses mainly on presenting the latest developments in CRISPR/Cas9 technology from four perspectives: homologous recombination, single base gene editing, off target effects, and epigenetic modifications. CRISPR/Cas9 technology is explored from three perspectives: cancer animal model construction, cancer mechanism research, and human embryo editing. In conclusion, CRISPR/Cas9’s therapeutic significance in immune diseases is described from two perspectives: gene repair and knockout as well as breaking collective immune tolerance.
Downloads
References
[1] Wu Y, Liang D, Wang Y, et al. Correction of a genetic disease in mouse via use of CRISPR-Cas9[J]. Cell stem cell, 2013, 13(6): 659-662.
[2] Ishino Y, Shinagawa H, Makino K, et al. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product[J]. J Bacteriol, 1987, 169(12): 5429-5433.
[3] Jansen R, Embden JD, Gaastra W, et al. Identification of genes that are associated with DNA repeats in prokaryotes [J]. Mol Microbiol, 2002, 43(6): 1565-1575.
[4] Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity[J]. Science, 2012, 337(6096): 816-821.
[5] Gasiunas G, Barrangou R, Horvath P, et al. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria[J]. Proc Natl Acad Sci U S A, 2012, 109(39): E2579-2586.
[6] Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems[J]. Science, 2013, 339(6121): 819-823.
[7] Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9[J]. Science, 2013, 339(6121): 823-826.
[8] Gilbert LA, Larson MH, Morsut L, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes[J]. Cell, 2013, 154(2): 442-451.
[9] Cheng AW, Wang H, Yang H, et al. Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system[J]. Cell Res, 2013, 23(10): 1163-1171.
[10] Chen B, Gilbert LA, Cimini BA, et al. Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/ Cas system[J]. Cell, 2013, 155(7): 1479-1491.
[11] Wang H, Yang H, Shivalila CS, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas- mediated genome engineering[J]. Cell, 2013, 153(4): 910- 918.
[12] Shen B, Zhang J, Wu H, et al. Generation of gene-modified mice via Cas9/RNA-mediated gene targeting [J]. Cell Res, 2013, 23(5): 720-723.
[13] Suzuki K, Tsunekawa Y, Hernandez-Benitez R, et al. In vivo genome editing via CRISPR/Cas9 mediated homology- independent targeted integration[J]. Nature, 2016, 540(7631): 144-149.
[14] Chu VT, Weber T, Wefers B, et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells[J]. Nat Biotechnol, 2015, 33(5): 543-548.
[15] Maruyama T, Dougan SK, Truttmann MC, et al. Increasing the efficiency of precise genome editing with CRISPR- Cas9 by inhibition of nonhomologous end joining[J]. Nat Biotechnol, 2015, 33(5): 538-542.
[16] Song J, Yang D, Xu J, et al. RS-1enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency[J]. Nat Commun, 2016, 7: 10548.
[17] Yao X, Wang X, Hu X, et al. Homology-mediated end joining-based targeted integration using CRISPR/Cas9[J]. Cell Res, 2017, 27(6): 801-814.
[18] Zhang JP, Li XL, Li GH, et al. Efficient precise knockin with a double cut HDR donor after CRISPR/Cas9-mediated double-stranded DNA cleavage[J]. Genome Biol, 2017, 18(1): 35.
[19] Yao X, Zhang M, Wang X, et al. Tild-CRISPR allows for efficient and precise gene knockin in mouse and human cells[J]. Dev Cell, 2018, 45(4): 526-536.e5.
[20] Gaudelli NM, Komor AC, Rees HA, et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage[J]. Nature, 2017, 551(7681): 464-471.
[21] Komor AC, Kim YB, Packer MS, et al. Programmable editing of a target base in genomic DNA without double- stranded DNA cleavage[J]. Nature, 2016, 533(7603):420-424.
[22] Komor AC, Zhao KT, Packer MS, et al. Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity[J]. Sci Adv, 2017, 3(8): eaao4774.
[23] Nishida K, Arazoe T, Yachie N, et al. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems[J]. Science, 2016, 353(6305)pii: aaf8729.
[24] Wang L, Xue W, Yan L, et al. Enhanced base editing by co- expression of free uracil DNA glycosylase inhibitor[J]. Cell Res, 2017, 27(10): 1289-1292.
[25] Zhou C, Zhang M, Wei Y, et al. Highly efficient base editing in human tripronuclear zygotes[J]. Protein Cell, 2017, 8(10): 772-775.
[26] Hu JH, Miller SM, Geurts MH, et al. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity[J]. Nature, 2018, 556(7699): 57-63.
[27] Anderson KR, Haeussler M, Watanabe C, et al. CRISPR off-target analysis in genetically engineered rats and mice[J]. Nat Methods, 2018, 15(7): 512-514.
[28] Jiang YH, Bressler J, Beaudet AL. Epigenetics and human disease[J]. Annu Rev Genomics Hum Genet, 2004, 5: 479-510.
[29] Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy[J]. Nature, 2004, 429(6990): 457-463.
[30] Jiang YH, Bressler J, Beaudet AL. Epigenetics and human disease[J]. Annu Rev Genomics Hum Genet, 2004, 5: 479-510.
[31] Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy[J]. Nature, 2004, 429(6990): 457-463.
[32] Rivenbark AG, Stolzenburg S, Beltran AS, et al. Epigenetic reprogramming of cancer cells via targeted DNA methylation[J]. Epigenetics, 2012, 7(4): 350-360.
[33] Bogdanove AJ, Voytas DF. TAL effectors: customizable proteins for DNA targeting[J]. Science, 2011, 333(6051): 1843-1846.
[34] Liu XS, Wu H, Ji X, et al. Editing DNA methylation in the mammalian genome[J]. Cell, 2016, 167(1): 233-247. e17.
[35] Liao HK, Hatanaka F, Araoka T, et al. In vivo target gene activation via CRISPR/Cas9-mediated trans-epigenetic modulation[J]. Cell, 2017, 171(7): 1495-1507. e15.
[36] Zhou H, Liu J, Zhou C, et al. In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR-dCas9-activator transgenic mice[J]. Nat Neurosci, 2018, 21(3): 440-446.
[37] Cheng AW, Jillette N, Lee P, et al. Casilio: a versatile CRISPR-Cas9-Pumilio hybrid for gene regulation and genomic labeling[J]. Cell Res, 2016, 26(2): 254-257.
[38] Niu Y, Shen B, Cui Y, et al. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos[J]. Cell, 2014, 156(4): 836-843.
[39] Yan S, Tu Z, Liu Z, et al. A huntingtin knockin pig model recapitulates features of selective neurodegeneration in huntington’s disease[J]. Cell, 2018, 173(4): 989-1002. e13.
[40] Dever DP, Bak RO, Reinisch A, et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells[J]. Nature, 2016, 539(7629): 384-389.
[41] Sciences N A O. CRISPR/Cas9 cleavages in budding yeast reveal templated insertions and strand-specific insertion/deletion profiles[J]. Proceedings of the National A- cademy of Sciences, 2018, 115(23):E5431-E5433.
[42] Zhang Qian, Li Li Progress in the Application of CRISPR/Cas9 Gene Editing Technology in the Research and Treatment of Gynecological Malignant Tumors [J]. Chin J Obstet Gynecol, 2018, 53(1):65-70.
[43] Jiang Shuchang, Shi Ming, Peng Hui. Application of CRISPR/Cas9 gene editing technique in cancer drug resistance: research advances [J]. J Int Pharm Res, 2017, 44 (4):299-305.
[44] Liang P, Xu Y, Zhang X, et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes[J]. Protein Cell, 2015, 6(5): 363-372.
[45] Kang X, He W, Huang Y, et al. Introducing precise genetic modifications into human 3PN embryos by CRISPR/Cas- mediated genome editing[J]. J Assist Reprod Genet, 2016, 33(5): 581-588.
[46] Ma H, Marti-Gutierrez N, Park SW, et al. Correction of a pathogenic gene mutation in human embryos[J]. Nature, 2017, 548(7668): 413-419.
[47] Fogarty NME, McCarthy A, Snijders KE, et al. Genome editing reveals a role for OCT4 in human embryogenesi[s J]. Nature, 2017, 550(7674): 67-73.
[48] Xiong Wei, Yang Yongqin, Zijiaji, et al. Application Progress of CRISPR-Cas9 Gene Editing Technology in Constructing Experimental Animal Tumor Models [J]. LETTERS IN BIOTECHNOLOGY, 2017, 28(4):551-557.
[49] Gomez M A, Lin Z D, Moll T. Simultaneous CRISPR/ Cas9-mediated editing of cassava eIF4E isoforms nCBP- 1 and nCBP-2 reduces cassava brown streak disease symptom severity and incidence [J]. Plant Biotechnology Journal,2018,17(2):89-91.
[50] Yu Z, Chen Q, Chen W l. Multigene editing via CRISPR/Cas9 guided by a single-sgRNA seed in Ara- bidopsis[J]. Journal of Integrative Plant Biology,2018,60 (5):376.
[51] Shi Yun. The application of CRISPR/Cas 9system in biological research and clinical trial [J]. Fudan Univ J Med Sci, 2018, 45(5):735-739.
[52] Shen Weinan, Xie Yangyang, Fan Xiaoxiang, et al. Application of CRISPR/Cas9 Gene Editing System in Colorectal Cancer [J]. Medical Recapitulate, 2018, 24(24):4852- 4857.
[53] Yang H, Wu J J, Tang T l.Author Correction: CRISPR/Cas9 -mediated genome editing efficiently creates spe- cific mutations at multiple loci using one sgRNA in Brassica napus[J].Scientific Reports,2018, 8(1):4877.
[54] Ma Yan, Ye Ziyu, Liang Yanfang, et al. Effect of CRISPR/Cas9-mediated IL-6 knockout on chemo-sensitivity in human colorectal cancer SW1116 cell line [J]. Chongqing Medical, 2018,47(32):4093-4097,4101.
[55] Cyranoski D. CRISPR gene-editing tested in a person for the first time[J]. Nature, 2016, 539(7630): 479.
[56] Reardon S. First CRISPR clinical trial gets green light from US panel[J/OL]. Nature News, 2016 (2016-06-22) [2018- 06-26]. https://www.nature.com/news/first-crispr-clinical- trial-gets-green-light-from-us-panel-1.20137.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
